Pfizer Inc. agreed to end a dispute with Hikma Pharmaceuticals Plc after one day of trial, resolving the last remaining ...

Pfizer has reached settlements with three drugmakers to delay US generic competition for its $6.4 billion heart drug Vyndamax until 2031, extending revenue stability amid looming industry pressures.

Relay Therapeutics (NASDAQ:RLAY) outlined new data and development plans for its lead oncology program, zovegalisib, during a “frontline breast cancer update” conference call, highlighting encouraging ...

Novavax secures a non-exclusive licensing deal with Pfizer, validating Matrix-M's platform value and shifting NVAX toward a technology provider model. NVAX receives $30M upfront, a potential $500M in ...

Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or ...

NEW YORK(AP) — U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind ...

SHANGHAI, Feb 24 (Reuters) - Pfizer (PFE) has entered an agreement to license Sciwind Biosciences' type 2 diabetes treatment ‌ecnoglutide, with potential payments of up to $495 million ‌if milestones ...

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to ...

Pfizer announced Tuesday that it had entered an agreement with the UN that will expand access of its new COVID-19 antiviral pill to millions of people in poorer countries upon its approval. In a press ...

(Reuters) - Pfizer Inc, beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to ...